PTC Adds To Management Team In Sign Of Progress Beyond Setbacks
This article was originally published in The Pink Sheet Daily
Executive Summary
The New Jersey-based biotech has not lost its optimism after a setback in Europe for its lead product and is showing growth in other areas.
You may also be interested in...
Sarepta Continues To Show Results In DMD, But Is It Enough?
The biotech announced positive results from a small Phase IIb study, but investors are wary and it’s still unclear whether regulators will consider the data to be clear cut enough for approval.
Sarepta Continues To Show Results In DMD, But Is It Enough?
The biotech announced positive results from a small Phase IIb study, but investors are wary and it’s still unclear whether regulators will consider the data to be clear cut enough for approval.
Prosensa Finds Path Forward For Drisapersen In DMD Drug Revival
The Dutch company received positive news for its development programs in the U.S., an encouraging sign for a disease space that has been flailing in recent months due to unclear clinical endpoints.